Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Nationwide Surveillance Study of Vancomycin-Intermediate Staphylococcus aureus Strains in Korean Hospitals from 2001 to 2006

  • Chung, Gyung-Tae (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health) ;
  • Cha, Jeong-Ok (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health) ;
  • Han, Sun-Young (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health) ;
  • Jang, Hee-Sun (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health) ;
  • Lee, Kyeong-Min (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health) ;
  • Yoo, Jae-Il (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health) ;
  • Yoo, Jeong-Sik (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health) ;
  • Kim, Hong-Bin (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Eun, Soo-Hoon (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health) ;
  • Kim, Bong-Su (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health) ;
  • Park, Ok (Infectious Disease Surveillance Team, Korea Center for Disease Control and Prevention) ;
  • Lee, Yeong-Seon (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health)
  • Received : 2009.06.11
  • Accepted : 2009.10.26
  • Published : 2010.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

We investigated the prevalence and the molecular characteristics of vancomycin-intermediate Staphylococcus aureus (VISA) among methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from clinical samples at tertiary or general hospitals participating in a nationwide surveillance program for VISA and vancomycin-resistant Staphylococcus aureus (VRSA) in Korea during an 8-week period in each year from 2001 to 2006. Of 41,639 MRSAs isolated, 37,856 were screened and 169 grew on brain heart infusion agar supplemented with 4 ${\mu}g/ml$ vancomycin. A vancomycin MIC of 4 ${\mu}g/ml$ was confirmed for 33 VISA isolates of the 169 isolates. Eighteen of the 33 isolates were classified as hetero-VISA (hVISA) by the population analysis profile (PAP) method. All VISA isolates were susceptible to linezolid, tigecycline, and quinupristin-dalfopristin. Most VISA isolates (MIC 4 ${\mu}g/ml$) showed a PFGE C pattern with sec, seg, and sei enterotoxin genes, including ST5-SCCmec type II, or a PFGE A pattern with sea, including ST239-SCCmec type III.

Keywords

References

  1. Aligholi, M., M. Emaneini, F. Jabalameli, S. Shahsavan, H. Dabiri, and H. Sedaght. 2008. Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini hospital in Tahran. Med. Princ. Pract. 17: 432-434. https://doi.org/10.1159/000141513
  2. Becker, K., R. Roth, and G. Peters. 1998. Rapid and specific detection of toxigenic Staphylococcus aureus: Use of two multiplex PCR enzyme immunoassays for amplification and hybridization of staphylococcal enterotoxin genes, exfoliative toxin genes, and toxic shock syndrome toxin 1 gene. J. Clin. Microbiol. 36: 2548-2553.
  3. Bierbaum, G., K. Fuchs, W. Lenz, C. Szekat, and H. G. Sahl. 1999. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur. J. Clin. Microbiol. Infect. Dis. 18: 691-696. https://doi.org/10.1007/s100960050380
  4. Centers for Diseases Control and Prevention. 1999. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois. MMWR 48: 1165-1167.
  5. Centers for Diseases Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin - United States. MMWR 51: 565-567.
  6. Clark, N. C., R. C. Cooksey, B. C. Hill, J. M. Swenson, and F. C. Tenover. 1993. Characterization of glycopeptides-resistant enterococci from U.S. hospitals. Antimicrob. Agents Chemother. 37: 2311-2317. https://doi.org/10.1128/AAC.37.11.2311
  7. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard 7th Ed. Document M7-A7. CLSI, Wayne, PA.
  8. Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 1079-1082. https://doi.org/10.1128/AAC.50.3.1079-1082.2006
  9. Denis, O., C. Nonhoff, B. Byl, C. Knoop, S. Bobin-Dubreux, and M. J. Struelens. 2002. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: Microbiological and clinical features. J. Antimicrob. Chemother. 50: 383-391. https://doi.org/10.1093/jac/dkf142
  10. Finks, J., E. Wells, T. L. Dyke, N. Husain, L. Plizga, R. Heddurshetti, et al. 2009. Vancomycin-resistant Staphylococcus aureus, Michigan, U.S.A., 2007. Emerg. Infect. Dis. 15: 943-945. https://doi.org/10.3201/eid1506.081312
  11. Goldstein, F. 2007. The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 59: 1-4.
  12. Guerin, F., A. Buu-Hoi, J. L. Mainardi, G. Kac, N. Colardelle, S. Vaupre, L. Gutmann, and I. Podglajen. 2000. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J. Clin. Microbiol. 38: 2985-2988.
  13. Hanaki, H., Y. Hososaka, C. Yanagisawa, Y. Otsuka, Z. Nagasawa, T. Nakae, and K. Sunakawa. 2007. Occurrence of vancomycinintermediate-resistant Staphylococcus aureus in Japan. J. Infect. Chemother. 13: 118-121. https://doi.org/10.1007/s10156-006-0498-z
  14. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350: 1670-1673. https://doi.org/10.1016/S0140-6736(97)07324-8
  15. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oquri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40: 135-136. https://doi.org/10.1093/jac/40.1.135
  16. Hussain, F. M., S. Boyle-Vavra, P. B. Shete, and R. S. Daum. 2002. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J. Infect. Dis. 186: 661-667. https://doi.org/10.1086/342708
  17. Ike, Y., Y. Arakawa, X. Ma, K. Tatewaki, M. Nagasawa, H. Tomita, K. Tanimoto, and S. Fujimoto. 2001. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J. Clin. Microbiol. 39: 4445-4451. https://doi.org/10.1128/JCM.39.12.4445-4451.2001
  18. Kim, H. B., Y. S. Lee, B. S. Kim, J. O. Cha, S. U. Kwon, H. J. Lee, et al. 2006. Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 microg/ml Korea. Microb. Drug Res. 12: 33-38. https://doi.org/10.1089/mdr.2006.12.33
  19. Kim, M. N., C. H. Pai, J. H. Woo, J. S. Ryu, and K. Hiramatsu. 2000. Vancomycin-intermediate Staphylococcus aureus in Korea. J. Clin. Microbiol. 38: 3879-3881.
  20. Kim, M. N., S. H. Hwang, Y. J. Pyo, H. M. Mun, and C. H. Pai. 2002. Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. J. Clin. Microbiol. 40: 1376-1380. https://doi.org/10.1128/JCM.40.4.1376-1380.2002
  21. Lee, K., C. L. Chang, N. Y. Lee, H. S. Kim, K. S. Hong, and H. C. Cho. 2000. Korean nationwide surveillance of antimicrobial resistance of bacteria in 1998. Yonsei Med. J. 41: 497-506.
  22. Lulitanond, A., C. Engchanil, P. Chaimanee, M. Vorachit, T. Ito, and H. Keiichi. 2009. The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand. J. Clin. Microbiol. 47: 2311-2316. https://doi.org/10.1128/JCM.01749-08
  23. Marchese, A., G. Balistreri, E. Tonoli, E. A. Debbla, and G. C. Schito. 2000. Heterogeneous vancomycin resistance in methicillinresistant Staphylococcus aureus strains in a large Italian hospital. J. Clin. Microbiol. 38: 866-869.
  24. Monday, S. R. and G. A. Bohach. 1999. Use of multiplex PCR to detect classical and newly described pyrogenic toxin genes in staphylococcal isolates. J. Clin. Microbiol. 37: 3411-3414.
  25. Moore, M. R., F. Perdreau-Remington, and H. F. Chambers. 2003. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 47: 1262-1266. https://doi.org/10.1128/AAC.47.4.1262-1266.2003
  26. Oliveira, D. C. and H. de Lencastre. 2002. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 2155-2161. https://doi.org/10.1128/AAC.46.7.2155-2161.2002
  27. Poly, M. C., C. Grelaud, C. Martin, L. de Lumley, and F. Denis. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351: 1212.
  28. Reverdy, M. E., S. Jarraud, S. Bobin-Dubreux, E. Burel, P. Girardo, G. Lina, F. Vandenesch, and J. Etienne. 2001. Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals. Clin. Microbiol. Infect. 7: 267-272. https://doi.org/10.1046/j.1198-743x.2001.00256.x
  29. Roberts, J., R. Bismuth, and V. Jarlier. 2006. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: A 20 year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 57: 506-510. https://doi.org/10.1093/jac/dki486
  30. Rybak, M. J., S. N. Leonard, K. L. Rossi, C. M. Cheung, H. S. Sadar, and R. N. Jones. 2008. Characterization of vancomycinheteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 46: 2950-2954. https://doi.org/10.1128/JCM.00582-08
  31. Saha, B., A. K. Singh, A. Ghosh, and M. Bal. 2008. Identification and characterization of vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J. Med. Microbiol. 57: 72-79. https://doi.org/10.1099/jmm.0.47144-0
  32. Sieradzki, K., R. B. Roberts, S. W. Harber, and A. Tomasz. 1999. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med. 340: 517-523. https://doi.org/10.1056/NEJM199902183400704
  33. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, et al. 1999. Emergence of Vancomycin Resistance in Staphylococcus aureus Working Group. N. Engl. J. Med. 340: 493-501. https://doi.org/10.1056/NEJM199902183400701
  34. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing. J. Clin. Microbiol. 33: 2233-2239.
  35. Tiwari, H. K. and M. R. Sen. 2006. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect. Dis. 6: 156-161. https://doi.org/10.1186/1471-2334-6-156
  36. Van Griethuysen, A., A. Van't Veen, A. Buiting, T. Walsh, and J. Kluytmans. 2003. High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands. J. Clin. Microbiol. 41: 2487-2491. https://doi.org/10.1128/JCM.41.6.2487-2491.2003
  37. Wong, S. S. Y., P. L. Ho, P. C. Y. Woo, and K. Y. Yuen. 1999. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin. Infect. Dis. 29: 760-767. https://doi.org/10.1086/520429
  38. Wootton, M., R. A. Howe, R. Hillman, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a U.K. hospital. J. Antimicrob. Chemother. 47: 399-403. https://doi.org/10.1093/jac/47.4.399

Cited by

  1. The crisis of antimicrobial resistance: current status and future strategies vol.53, pp.11, 2010, https://doi.org/10.5124/jkma.2010.53.11.999
  2. Damage of staphylococcal cytoplasmic membrane by Quercus infectoria G. Olivier and its components vol.52, pp.6, 2011, https://doi.org/10.1111/j.1472-765x.2011.03041.x
  3. Efficacy of Vancomycin againstStaphylococcus aureusaccording to Inoculum Size in a Neutropenic Mouse Infection Model vol.43, pp.3, 2010, https://doi.org/10.3947/ic.2011.43.3.251
  4. Antimicrobial Resistance in Gram-positive Cocci: Past 50 Years, Present and Future vol.43, pp.6, 2010, https://doi.org/10.3947/ic.2011.43.6.443
  5. Downregulation of RNAIII in vancomycin-intermediate Staphylococcus aureus strains regardless of the presence of agr mutation vol.61, pp.3, 2010, https://doi.org/10.1099/jmm.0.035204-0
  6. The usefulness of arbekacin compared to vancomycin vol.31, pp.7, 2010, https://doi.org/10.1007/s10096-011-1490-9
  7. Sentinel Surveillance and Molecular Epidemiology of Multidrug Resistance Bacteria vol.15, pp.2, 2012, https://doi.org/10.5145/kjcm.2012.15.2.43
  8. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare vol.25, pp.4, 2010, https://doi.org/10.1097/qco.0b013e3283553441
  9. Changes in Antimicrobial Susceptibility of Blood Isolates in a University Hospital in South Korea, 1998-2010 vol.44, pp.4, 2010, https://doi.org/10.3947/ic.2012.44.4.275
  10. Prevalence of amino acid changes in the yvqF, vraSR, graSR, and tcaRAB genes from vancomycin intermediate resistant Staphylococcus aureus vol.51, pp.2, 2010, https://doi.org/10.1007/s12275-013-3088-7
  11. Multidrug‐Resistant Organisms in Dialysis Patients vol.26, pp.4, 2010, https://doi.org/10.1111/sdi.12094
  12. The Efficacy and Safety of Arbekacin and Vancomycin for the Treatment in Skin and Soft Tissue MRSA Infection: Preliminary Study vol.45, pp.1, 2010, https://doi.org/10.3947/ic.2013.45.1.62
  13. Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates vol.10, pp.8, 2010, https://doi.org/10.1371/journal.pone.0136082
  14. Molecular epidemiology of heteroresistant vancomycin-intermediate Staphylococcus aureus in Brazil vol.19, pp.5, 2010, https://doi.org/10.1016/j.bjid.2015.06.013
  15. Molecular Typing and Resistance Profiles of Vancomycin-IntermediateStaphylococcus aureusin Korea: Results from a National Surveillance Study, 2007-2013 vol.19, pp.4, 2010, https://doi.org/10.5145/acm.2016.19.4.88
  16. 최근 8년간 혈액배양에서 분리된 미생물의 항균제 감수성 양상: 2010~2017 vol.51, pp.2, 2010, https://doi.org/10.15324/kjcls.2019.51.2.155
  17. Novel spa and Multi-Locus Sequence Types (MLST) of Staphylococcus Aureus Samples Isolated from Clinical Specimens in Korean vol.8, pp.4, 2010, https://doi.org/10.3390/antibiotics8040202
  18. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta- vol.10, pp.None, 2010, https://doi.org/10.1038/s41598-020-69058-z